EPC2 Inhibitors
EPC2 inhibitors belong to a chemical class of compounds specifically designed to target and modulate the activity of the EPC2 protein. EPC2, or Enhancer of Polycomb 2, is a crucial component of the Polycomb Repressive Complex 2 (PRC2), a multi-subunit complex involved in epigenetic regulation of gene expression and chromatin remodeling. As part of the PRC2 complex, EPC2 plays an essential role in maintaining gene silencing and controlling cell fate decisions during development. Inhibiting EPC2 activity with these compounds is a critical step in studying the mechanisms of PRC2-mediated gene regulation and understanding its impact on various cellular processes. The chemical structure of EPC2 inhibitors encompasses diverse compounds, including small organic molecules and larger biomolecules. These inhibitors are carefully designed to interact with specific regions of the EPC2 protein, effectively disrupting its function or altering its conformation. Some EPC2 inhibitors act as competitive antagonists, binding to the active site or other crucial regions of the protein, thus inhibiting its activity. Others may exert their inhibitory effects through allosteric regulation, influencing EPC2's function indirectly by binding to distinct sites on the protein.
The discovery and development of EPC2 inhibitors often involve a combination of computational modeling, high-throughput screening, and structure-activity relationship studies. Researchers aim to optimize the inhibitory potency and selectivity of these compounds, ensuring their effectiveness in specifically targeting EPC2 while minimizing interactions with other cellular components. In experimental settings, EPC2 inhibitors serve as valuable tools to investigate the functional role of this protein in PRC2-mediated gene regulation and chromatin remodeling. By inhibiting EPC2, researchers can study the consequences of PRC2 dysfunction, unravel the epigenetic control of gene expression, and explore the impact of altered PRC2 activity on cellular processes such as development, differentiation, and cellular homeostasis.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GSK126 | 1346574-57-9 | sc-490133 sc-490133A sc-490133B | 1 mg 5 mg 10 mg | $92.00 $243.00 $306.00 | ||
GSK126 is a potent and selective inhibitor of the catalytic subunit of PRC2, EZHAs EPC2 is part of the PRC2 complex, GSK126 can indirectly affect EPC2 function. | ||||||
EPZ005687 | 1396772-26-1 | sc-497734 | 2.5 mg | $380.00 | ||
EPZ005687 is another selective inhibitor of EZH2, which can modulate the activity of the PRC2 complex, including EPC2. | ||||||
UNC1999 | 1431612-23-5 | sc-475314 | 5 mg | $142.00 | 1 | |
UNC1999 is a small molecule inhibitor that targets both EZH2 and EED, a core subunit of PRCAs EPC2 interacts with EED in the PRC2 complex, UNC1999 can potentially impact EPC2 function. | ||||||
GSK343 | 1346704-33-3 | sc-397025 sc-397025A | 5 mg 25 mg | $151.00 $461.00 | 1 | |
GSK343 is a selective inhibitor of the PRC2 complex, including its core component EPCIt specifically inhibits the catalytic activity of the PRC2 complex. | ||||||
CPI-360 | 1802175-06-9 | sc-507464 | 1 mg | $100.00 | ||
CPI-360 is an inhibitor of EZH2, the catalytic subunit of PRCIts effects on EZH2 activity can also affect the function of the entire PRC2 complex, including EPC2. | ||||||
EPZ6438 | 1403254-99-8 | sc-507456 | 1 mg | $66.00 | ||
EPZ-6438 is a clinical-stage EZH2 inhibitor, which can indirectly influence EPC2 function by targeting the catalytic subunit of PRC2. | ||||||